CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
Ramucirumab (IMC-1121B ) +1 morebiological
Likely dose
Ramucirumab (IMC-1121B ) 8 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253525
NCT01253525Phase 1Completed
CompareCT.gov

A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas

Eli Lilly and Company·interventional·Posted Dec 3, 2010·Updated Jun 18, 2014

In Brief

A Phase 1 clinical trial evaluating Ramucirumab (IMC-1121B ) and Paclitaxel for Adenocarcinoma. Completed, enrolled 6 participants across 3 sites.

Detailed Summary

Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartNov 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.6 years ago

Interventions

Ramucirumab (IMC-1121B )biological

8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle

Paclitaxeldrug

80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle